Developer docs
API playgroundTry for free, no card

Search company profiles

Cancer52

Full company profile

uuid0042tp2

Namestring
Cancer52
Legal namestring
Cancer52
Websiteurl
cancer52.org.uk
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Cancer52 is a UK-registered charity alliance (registered charity number 1174569; company limited by guarantee number 7994413) comprising over 100 cancer charities that focus on rare and less common cancers — defined as those outside the four most common types (breast, bowel, lung, prostate). The organization, headquartered in London and operating with approximately 11 employees under CEO Jane Lyons, was founded in 2006 and exists to address a documented inequality: rare and less common cancers account for 47% of UK cancer diagnoses and 55% of UK cancer deaths, yet have historically been under-represented in policy, services, and research funding.

The alliance operates as a convening and advocacy platform rather than a technology product company. Its core activities include unifying, informing, and empowering member organizations; capturing the patient voice through surveys and case studies; and transmitting that voice to policymakers, the NHS, NICE, NCRI, and research institutions. Service and publication assets include the annual Big Cancer52 Conversation (a flagship event series launched in 2023 and expanded to multiple UK cities), the Research Spend Report (co-developed with NCRI), the State of the Nation Report, the Improving Diagnosis Report (co-developed with GRAIL and Incisive Health), the ACT NOW for Cancer initiative, a rare cancers directory, a health information resource library, and recurring member bulletins.

Cancer52's revenue model is donation-based, supported through the JustGiving platform, with additional income from event sponsorship (including from GSK and The National Lottery Community Fund) and likely member contributions. It does not charge for membership or services and has no publicly disclosed revenue figure. The organization holds no patents, has not raised traditional funding rounds, and operates exclusively in the United Kingdom. Its competitive position rests on being the only coalition of its scale in this disease sub-segment, supported by formal partnerships with NHS England, NICE, NCRI, Genomics England, GRAIL, and Incisive Health.

Short descriptiontext

Cancer52 is a UK-registered charity alliance of over 100 cancer charities that advocates for patients with rare and less common cancers, which account for 47% of UK diagnoses and 55% of UK cancer deaths. Based in London with 11 employees under CEO Jane Lyons, it convenes members, publishes policy reports, and engages NHS England, NICE, and research bodies to influence cancer policy and funding.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer charity alliance, patient advocacy, rare cancer policy, cancer research reports, health policy influence
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Health Services8000
Product category
Cancer Charity Advocacy and Policy Influence
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Fundraising
TypeGrants Donations
Description

Cancer52 operates as a registered charity (1174569) and accepts donations through platforms like JustGiving to support its work as an alliance of cancer charities advocating for rare and less common cancer patients.

cancer52.org.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cancer52 is a charity alliance of over 100 cancer charities that unifies, informs and empowers member organizations while capturing the patient voice for rare and less common cancers and channeling it into national cancer policy, research, and service delivery. It delivers this through member communications, published reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), policy consultations, and the annual Big Cancer52 Conversation event.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cancer52 is a charity alliance organization, not a technology product company. It operates as a coalition of over 100 cancer charities united to address inequality in rare and less common cancers. The organization provides advocacy services, publishes research reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), hosts the annual Big Cancer52 Conversation event, maintains a directory of rare cancer charities, offers a health information resource library, and runs member bulletins and the ACT NOW for Cancer initiative. These services support the organization's mission to unify, inform, and empower member organizations while influencing cancer policy at national level.

Product and service8 records
1Cancer52 Charity Alliance
CategoryCore service
Description

Core membership coalition of over 100 UK cancer charities focused on rare and less common cancers, offering unified advocacy, policy engagement, and patient voice amplification for member organizations and the patients they serve.

2Research Spend Report
CategoryPublished report
Description

Published report analysing research funding by Cancer52 members and NCRI partners, documenting disparities between rare/less common cancers and common cancers, intended for policymakers, researchers and member charities.

3The Big Cancer52 Conversation
CategoryEvent
Description

Annual in-person event series bringing together member charities, policymakers, NHS bodies, clinicians and researchers to discuss rare and less common cancer policy, early diagnosis and care in the UK.

4Improving Diagnosis Report
CategoryPublished report
Description

Published report examining patient and clinician perspectives on increasing early diagnosis in rare and less common cancers, with policy recommendations for the National Cancer Plan for England.

5State of the Nation Report: No Cancer Too Rare
CategoryPublished report
Description

Policy review report examining developments since the 2024 UK General Election that will shape cancer services for rare and less common cancers.

6ACT NOW for Cancer
CategoryInitiative
Description

Initiative showcasing real-world case studies from Cancer52 member charities, demonstrating impact for people affected by rare and less common cancers.

7Rare and Less Common Cancers Directory
CategoryDirectory / information service
Description

Searchable directory of Cancer52 member charities organized by cancer type, helping patients, carers and the public find information and support for specific rare and less common cancers.

8Cancer52 Bulletins
CategoryPublication / newsletter
Description

Regular email bulletins providing member charities and stakeholders with updates on news, events, policy developments and organizational activities.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1GRAIL
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer52 worked with GRAIL (biotech company) on the 'Improving Diagnosis' report, collaborating on patient and clinician insights around early diagnosis for rare and less common cancers.

cancer52.org.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer52 collaborated with Incisive Health consultancy on the 'Improving Diagnosis' report, taking a deep dive led by patients, carers, and clinicians.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer52 engages with NHS England on cancer policy, early diagnosis initiatives, and the National Cancer Plan. The organization participates in consultations and provides patient voice input.

4NCRI (National Cancer Research Institute)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer52 collaborates with NCRI on the Research Spend Report, combining Cancer52 member data with NCRI partner data for comprehensive analysis of research spending on rare and less common cancers.

cancer52.org.uk
5Genomics England
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genomics England hosts Cancer52 Roundtable discussions, providing a platform for engagement on genomics and rare cancer research.

cancer52.org.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cancer52 engages with NICE on public involvement programmes and consultations, contributing patient perspectives to NICE methods and processes reviews.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The UK's largest cancer charity, funding research, influencing policy and providing patient information. Overlaps significantly with Cancer52's policy and research-funding advocacy remit but as a single, much larger organisation rather than an alliance.

TypeDirect peer
Description

UK charity alliance representing hundreds of patient organisations supporting people affected by genetic, rare and undiagnosed conditions. Operates a near-identical coalition model advocating for under-represented patient communities in NHS and policy fora.

TypeBroad incumbent
Description

Major UK cancer charity providing services and influencing policy on cancer patient experience. Comparable in policy influence scope to Cancer52 but operates as a single direct-service charity rather than a charity alliance.

TypeEmerging player
Description

UK charity focused on blood cancers and stem-cell transplantation. A Cancer52 member-style organisation operating in a specific rare cancer niche, illustrating the scale and specialisation of Cancer52's constituent members.

TypeRegional player
Description

US-based federation of patient organisations and advocacy groups for rare diseases. Functions as the American equivalent of Cancer52's coalition model but in a different regulatory and payer environment.

TypeEmerging player
Description

UK charity dedicated to blood cancer research and patient support. Representative of the type of single-disease member charity within Cancer52's alliance, illustrating the typical size and remit of Cancer52's 100+ member organisations.

TypeDirect peer
Description

UK national campaign run by Genetic Alliance UK focused specifically on rare diseases. Highly comparable alliance-style advocacy structure targeting the same NHS policy-making environment that Cancer52 engages with.

8National Cancer Research Institute (NCRI)
TypeOthers
Description

UK partnership of cancer research funders that Cancer52 actively collaborates with on the Research Spend Report. An adjacent ecosystem participant rather than a competitor, but sharing the policy and research coordination function Cancer52 performs for charities.

TypeDirect peer
Description

European alliance of over 1,000 rare-disease patient organisations. Operates an analogous multi-charity advocacy and policy-influence model with which Cancer52 shares NHS-aligned patient representation objectives.

TypeDirect peer
Description

European umbrella coalition of over 400 cancer patient organisations. The most direct continental analogue to Cancer52's cancer-charity alliance model, operating across jurisdictions but with the same advocacy and patient-voice mandate.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cancer52

Cancer Charity Advocacy and Policy Influencecancer52.org.uk

Cancer52 is a UK-registered charity alliance of over 100 cancer charities that advocates for patients with rare and less common cancers, which account for 47% of UK diagnoses and 55% of UK cancer deaths. Based in London with 11 employees under CEO Jane Lyons, it convenes members, publishes policy reports, and engages NHS England, NICE, and research bodies to influence cancer policy and funding.

What Cancer52 does

Cancer52 is a UK-registered charity alliance (registered charity number 1174569; company limited by guarantee number 7994413) comprising over 100 cancer charities that focus on rare and less common cancers — defined as those outside the four most common types (breast, bowel, lung, prostate). The organization, headquartered in London and operating with approximately 11 employees under CEO Jane Lyons, was founded in 2006 and exists to address a documented inequality: rare and less common cancers account for 47% of UK cancer diagnoses and 55% of UK cancer deaths, yet have historically been under-represented in policy, services, and research funding.

The alliance operates as a convening and advocacy platform rather than a technology product company. Its core activities include unifying, informing, and empowering member organizations; capturing the patient voice through surveys and case studies; and transmitting that voice to policymakers, the NHS, NICE, NCRI, and research institutions. Service and publication assets include the annual Big Cancer52 Conversation (a flagship event series launched in 2023 and expanded to multiple UK cities), the Research Spend Report (co-developed with NCRI), the State of the Nation Report, the Improving Diagnosis Report (co-developed with GRAIL and Incisive Health), the ACT NOW for Cancer initiative, a rare cancers directory, a health information resource library, and recurring member bulletins.

Cancer52's revenue model is donation-based, supported through the JustGiving platform, with additional income from event sponsorship (including from GSK and The National Lottery Community Fund) and likely member contributions. It does not charge for membership or services and has no publicly disclosed revenue figure. The organization holds no patents, has not raised traditional funding rounds, and operates exclusively in the United Kingdom. Its competitive position rests on being the only coalition of its scale in this disease sub-segment, supported by formal partnerships with NHS England, NICE, NCRI, Genomics England, GRAIL, and Incisive Health.

Cancer52 firmographics

Firmographics
Name
Cancer52
Legal name
Cancer52
Website
https://cancer52.org.uk
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Cancer52 is a UK-registered charity alliance of over 100 cancer charities that advocates for patients with rare and less common cancers, which account for 47% of UK diagnoses and 55% of UK cancer deaths. Based in London with 11 employees under CEO Jane Lyons, it convenes members, publishes policy reports, and engages NHS England, NICE, and research bodies to influence cancer policy and funding.
Ownership category
akta.pro rank

Where Cancer52 is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Cancer52 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Donations and Fundraising: Cancer52 operates as a registered charity (1174569) and accepts donations through platforms like JustGiving to support its work as an alliance of cancer charities advocating for rare and less common cancer patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cancer52 product offering

Product offering

Core offering

Cancer52 is a charity alliance of over 100 cancer charities that unifies, informs and empowers member organizations while capturing the patient voice for rare and less common cancers and channeling it into national cancer policy, research, and service delivery. It delivers this through member communications, published reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), policy consultations, and the annual Big Cancer52 Conversation event.

Product overview

Cancer52 is a charity alliance organization, not a technology product company. It operates as a coalition of over 100 cancer charities united to address inequality in rare and less common cancers. The organization provides advocacy services, publishes research reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), hosts the annual Big Cancer52 Conversation event, maintains a directory of rare cancer charities, offers a health information resource library, and runs member bulletins and the ACT NOW for Cancer initiative. These services support the organization's mission to unify, inform, and empower member organizations while influencing cancer policy at national level.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cancer52 Charity Alliance Core membership coalition of over 100 UK cancer charities focused on rare and less common cancers, offering unified advocacy, policy engagement, and patient voice amplification for member organizations and the patients they serve.
  • Research Spend Report Published report analysing research funding by Cancer52 members and NCRI partners, documenting disparities between rare/less common cancers and common cancers, intended for policymakers, researchers and member charities.
  • The Big Cancer52 Conversation Annual in-person event series bringing together member charities, policymakers, NHS bodies, clinicians and researchers to discuss rare and less common cancer policy, early diagnosis and care in the UK.
  • Improving Diagnosis Report Published report examining patient and clinician perspectives on increasing early diagnosis in rare and less common cancers, with policy recommendations for the National Cancer Plan for England.
  • State of the Nation Report: No Cancer Too Rare Policy review report examining developments since the 2024 UK General Election that will shape cancer services for rare and less common cancers.
  • ACT NOW for Cancer Initiative showcasing real-world case studies from Cancer52 member charities, demonstrating impact for people affected by rare and less common cancers.
  • Rare and Less Common Cancers Directory Searchable directory of Cancer52 member charities organized by cancer type, helping patients, carers and the public find information and support for specific rare and less common cancers.
  • Cancer52 Bulletins Regular email bulletins providing member charities and stakeholders with updates on news, events, policy developments and organizational activities.

Companies that use Cancer52

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Cancer52 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cancer52 partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • GRAILcoreStrategic or Co-development PartnerCancer52 worked with GRAIL (biotech company) on the 'Improving Diagnosis' report, collaborating on patient and clinician insights around early diagnosis for rare and less common cancers.
  • Incisive HealthcoreStrategic or Co-development PartnerCancer52 collaborated with Incisive Health consultancy on the 'Improving Diagnosis' report, taking a deep dive led by patients, carers, and clinicians.
  • NHS EnglandcoreStrategic or Co-development PartnerCancer52 engages with NHS England on cancer policy, early diagnosis initiatives, and the National Cancer Plan. The organization participates in consultations and provides patient voice input.
  • NCRI (National Cancer Research Institute)coreStrategic or Co-development PartnerCancer52 collaborates with NCRI on the Research Spend Report, combining Cancer52 member data with NCRI partner data for comprehensive analysis of research spending on rare and less common cancers.
  • Genomics EnglandcoreStrategic or Co-development PartnerGenomics England hosts Cancer52 Roundtable discussions, providing a platform for engagement on genomics and rare cancer research.
  • NICEcoreStrategic or Co-development PartnerCancer52 engages with NICE on public involvement programmes and consultations, contributing patient perspectives to NICE methods and processes reviews.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Cancer52 competitors and assessment

Company assessment

Broad incumbents

  • Cancer Research UK: The UK's largest cancer charity, funding research, influencing policy and providing patient information. Overlaps significantly with Cancer52's policy and research-funding advocacy remit but as a single, much larger organisation rather than an alliance.
  • Macmillan Cancer Support: Major UK cancer charity providing services and influencing policy on cancer patient experience. Comparable in policy influence scope to Cancer52 but operates as a single direct-service charity rather than a charity alliance.

Direct peers

  • Genetic Alliance UK: UK charity alliance representing hundreds of patient organisations supporting people affected by genetic, rare and undiagnosed conditions. Operates a near-identical coalition model advocating for under-represented patient communities in NHS and policy fora.
  • Rare Disease UK: UK national campaign run by Genetic Alliance UK focused specifically on rare diseases. Highly comparable alliance-style advocacy structure targeting the same NHS policy-making environment that Cancer52 engages with.
  • EURORDIS - Rare Diseases Europe: European alliance of over 1,000 rare-disease patient organisations. Operates an analogous multi-charity advocacy and policy-influence model with which Cancer52 shares NHS-aligned patient representation objectives.
  • European Cancer Patient Coalition: European umbrella coalition of over 400 cancer patient organisations. The most direct continental analogue to Cancer52's cancer-charity alliance model, operating across jurisdictions but with the same advocacy and patient-voice mandate.

Emerging players

  • Anthony Nolan: UK charity focused on blood cancers and stem-cell transplantation. A Cancer52 member-style organisation operating in a specific rare cancer niche, illustrating the scale and specialisation of Cancer52's constituent members.
  • Blood Cancer UK: UK charity dedicated to blood cancer research and patient support. Representative of the type of single-disease member charity within Cancer52's alliance, illustrating the typical size and remit of Cancer52's 100+ member organisations.

Regional players

  • National Organization for Rare Disorders (NORD): US-based federation of patient organisations and advocacy groups for rare diseases. Functions as the American equivalent of Cancer52's coalition model but in a different regulatory and payer environment.

Others

  • National Cancer Research Institute (NCRI): UK partnership of cancer research funders that Cancer52 actively collaborates with on the Research Spend Report. An adjacent ecosystem participant rather than a competitor, but sharing the policy and research coordination function Cancer52 performs for charities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Cancer52 social profiles

Digital presence

Cancer52 compliance and trust

Trust signal

Compliance2 records

Cancer52 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cancer52 leadership team

Management profile

Number of profiles

Profiles1 record

Cancer52 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cancer52 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer52

What does Cancer52 do?

Cancer52 is a charity alliance of over 100 cancer charities that unifies, informs and empowers member organizations while capturing the patient voice for rare and less common cancers and channeling it into national cancer policy, research, and service delivery. It delivers this through member communications, published reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), policy consultations, and the annual Big Cancer52 Conversation event.

Is Cancer52 a public or private company?

Cancer52 is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cancer52 founded?

Cancer52 was founded in 2006. It employs 1 to 10 people.

Where is Cancer52 based?

Cancer52 is headquartered in London, United Kingdom, in the Europe region.

How does Cancer52 make money?

One revenue line is on record: donations and Fundraising.

Who are Cancer52's main competitors?

Broad incumbents on record are Cancer Research UK and Macmillan Cancer Support. Direct peers are Genetic Alliance UK, Rare Disease UK, EURORDIS - Rare Diseases Europe and European Cancer Patient Coalition. Emerging players are Anthony Nolan and Blood Cancer UK. National Organization for Rare Disorders (NORD) is listed as a regional player. National Cancer Research Institute (NCRI) is listed as an others.

Does Cancer52 have an API?

No public API is recorded for Cancer52.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales